You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non-squamous NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)

Not yet recruiting
  • Non-squamous NSCLC
  • paclitaxel polymeric micelles for injection
  • Nanjing, Jiangsu, China
  • +1 more
Mar 13, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center
May 22, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage II
  • +3 more
  • Serplulimab combined with bevacizumab and first-line chemotherapy
  • Guangzhou, Guangdong, China
    Likun Chen
Apr 10, 2023

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Non-squamous NSCLC, EGFR Gene Mutation Trial in Chengdu (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Not yet recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
  • Chengdu, Sichuan, China
  • +2 more
May 24, 2022

PFS, OS Trial in Qingdao (PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed)

Recruiting
  • PFS
  • OS
  • PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
  • Qingdao, Shandong, China
    Qingdao central Hospital
Feb 23, 2022

Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

Active, not recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • FSRT combined with Bevacizumab
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line

Completed
  • Non-squamous NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

    Recruiting
    • Non-Squamous Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Sep 22, 2022

    NSCLC Metastatic Trial in Salt Lake City (Durvalumab, Pemetrexed, Carboplatin)

    Recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Salt Lake City, Utah
      Huntsman Cancer Institute at University of Utah
    Mar 1, 2022

    Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

    Terminated
    Has Results
    • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    • +3 more
    • Anderson, Indiana
    • +8 more
    Jul 7, 2022

    NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +8 more
    • New Haven, Connecticut
      Yale University
    Oct 26, 2022

    Non-Squamous NSCLC Trial in Guangzhou (AK112 Injection, Placebo Injection)

    Recruiting
    • Non-Squamous Non-small Cell Lung Cancer
    • AK112 Injection
    • Placebo Injection
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 23, 2022

    NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Telisotuzumab Vedotin
    • +4 more
    • (no location specified)
    Oct 17, 2023

    NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Wuhan, Hubei, China
      Qian Chu
    Aug 18, 2023

    NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Feb 16, 2023

    Non-Squamous Non Small Cell Lung Cancer Trial in Changsha (Anlotinib and Docetaxel)

    Recruiting
    • Non-Squamous Non Small Cell Lung Cancer
    • Anlotinib and Docetaxel
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Advanced Non-squamous NSCLC Trial in Beijing (TQB2450 injection, Tilelizumab injection, Anlotinib HCl capsule, Pemetrexed

    Recruiting
    • Advanced Non-squamous Non-small Cell Lung Cancer
    • TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences Cancer Hospital
    Apr 20, 2022

    Non Small Cell Lung Cancer Trial in Shanghai (Tislelizumab, Carboplatin, Pemetrexed)

    Recruiting
    • Non Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Nov 19, 2021

    Advanced Non Squamous NSCLC Trial in Beijing (Camrelizumab, Apatinib)

    Recruiting
    • Advanced Non Squamous NSCLC
    • Beijing, Beijing, China
      China
    Jun 27, 2021

    Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

    Not yet recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
    • +2 more
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    May 5, 2023